B. Riley Securities initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

424B5 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

EFFECT - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

S-3 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

EFFECT - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

424B3 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

S-1 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

D - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through key anticipated regulatory inflection pointsAdditional nonclinical studies are ongoing combining elraglusib with RAS inhibitors based on potential synergies and complimentary mechanisms of action CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through

CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of 2,464,286 shares of its common stock, including 321,428 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price, before underwriting discounts and commissions, for each share of com

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten public offering of 2,142,858 shares of its common stock at an offering price of $7.00 per share of common stock. Actuate has granted the underwriters a 30-day option to purchase up to 321,428 additional shares of its common stock sold in the offering at the public offering price per share, less underwriti

CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the public offering at the public offering price per share, less underwriting disc

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte's PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy in advanced pancreatic adenocarcinoma. The trial is being

- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer - Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) - Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone - Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP CHICAGO and FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the in

CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). The study demonstrated the use of machine learning an

Inclusion reflects continued growth and momentum in the company's mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced today that the Company will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27, as part of the 2025 Rus

- Expert Insights on Clinical Relevance and Scientific Rationale- The replay of the event is available on the Investor Relations section of the Actuate website CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced key takeaways from its Key Opinion Leader (KOL) event held on May 31, 2025 discussing the positive topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in com

HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)